Orchestra BioMed Exceeds Enrollment Target in BACKBEAT Trial

What Happened
On October 1, 2026 Orchestra BioMed (OBIO) announced via Form 8‑K and a press release that, as of September 30, 2026, the BACKBEAT Global Pivotal Trial had randomized 330 patients—exceeding the company’s previously announced target of 316. The BACKBEAT Trial evaluates Atrioventricular Interval Modulation (AVIM) Therapy in pacemaker‑indicated patients with uncontrolled hypertension despite medication. The trial is being conducted with strategic collaborator Medtronic and uses a protocol approved by the U.S. Food and Drug Administration.

Key Details

• 330 patients randomized as of Sept 30, 2026 (target was 316).
• Protocol specifies 284 evaluable randomized subjects for the primary endpoint analysis; 316 accounted for expected loss to follow‑up.
• Randomization occurred at 81 sites across 13 countries.
• BACKBEAT is a global pivotal trial; Medtronic is the strategic collaborator and potential commercialization partner, subject to regulatory approval.

Why It Matters
Meeting and exceeding the enrollment target means the study has achieved its planned sample size and can move forward toward the predefined primary endpoint analysis under the FDA‑approved protocol. For investors, this reduces the near‑term risk of enrollment delays and supports progress toward clinical data readouts and subsequent regulatory milestones tied to AVIM Therapy and the collaboration with Medtronic.